Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript

This may even involve them getting on the line and partnering with us in some of the appeals process. We’ve had that happen, and that’s ultimately part of our goal where a clinician voices their perspective on the utility of the test in their practice. So, that’s really what it comes down to. Quite a bit of change in the office. It’s a different experience. It’s more akin to, I guess, what some of the oncology testing is doing. But clinicians, when they see the clinical value of the test, they’re very willing to do this. It’s just, can you make it easy on my staff? I can’t afford to spend an hour of their day completing test requisitions or pulling medical records or this type of thing. And so, it’s a utilization tactic by the insurer, but we’re working to satisfy it.

As I said, we view them as a customer.

Andrew Brackmann: That’s great color. Thanks, guys.

Operator: Thank you. We’ve reached the end of our question-and-answer session. I’ll turn the floor over to John Aballi for closing remarks.

John Aballi: Great. Thanks. 2023 has gone by quick, was an exciting year, and I’m very proud of the progress we’ve made. We’re working towards a more profitable business and we’re well on our way. I believe we have the right strategy, the right efforts, and the appropriate resources to transform our organization. Thanks for your interest in Exagen and for joining the call today.

Operator: This concludes today’s conference. You may disconnect your lines at this time, and thank you for your participation.